| Literature DB >> 24278537 |
Young-Su Yang1, Jinsoo Lee, Soonjin Kwon, Heung-Sik Seo, Seong-Jin Choi, Hee-Jin Yu, Jeong-Ah Song, Kyuhong Lee, Byoung-Seok Lee, Jeong-Doo Heo, Kyu-Hyuk Cho, Chang-Woo Song.
Abstract
tert-Butyl acetate (TBAc) is an organic solvent, which is commonly used in architectural coatings and industrial solvents. It has recently been exempted from the definition of a volatile organic compound (VOC) by the Air Resources Board (ARB) . Since the use of TBAc as a substitute for other VOCs has increased, thus its potential risk in humans has also increased. However, its inhalation toxicity data in the literature are very limited. Hence, inhalation exposure to TBAc was carried out to investigate its toxic effects in this study. Adult male rats were exposed to TBAc for 4 h for 1 day by using a nose-only inhalation exposure chamber (low dose, 2370 mg/m(3) (500 ppm) ; high dose, 9482 mg/m(3) (2000 ppm) ) . Shamtreated control rats were exposed to clean air in the inhalation chamber for the same period. The animals were killed at 2, 7, and 15 days after exposure. At each time point, body weight measurement, bronchoalveolar lavage fluid (BALF) analysis, histopathological examination, and biochemical assay were performed. No treatment-related abnormal effects were observed in any group according to time course. Based on those findings, the median lethal concentration (LC50) of TBAc was over 9482 mg/m(3) in this study. According to the MSDS, the 4 h LC50 for TBAc for rats is over 2230 mg/m(3). We suggested that this value is changed and these findings may be applied in the risk assessment of TBAc which could be beneficial in a sub-acute study.Entities:
Keywords: Bronchoalveolar lavage fluid analysis; Inhalation toxicity; Nose-only inhalation exposure chamber; Rats; tert-Butyl acetate
Year: 2010 PMID: 24278537 PMCID: PMC3834500 DOI: 10.5487/TR.2010.26.4.293
Source DB: PubMed Journal: Toxicol Res ISSN: 1976-8257
Fig. 1.Inhalation chamber concentrations of TBAc for 4 h. The concentrations in each inhalation chamber were controlled bymixing TBAc vapor and high-efficiency particulate air (HEPA) -filteredair. They were monitored by gas chromatography using a flame ionization detector-equipped chromatograph and silicone DC-200 column with 20% Chromosorb.
Body weights of rats exposed to TBAc vapor by inhalation. Three groups of 18 rats (each group, 6 rats) were exposed to TBAc at concentrations of 0, 500, and 2000 ppm for 4h
| Control (g) | 500 ppm (g) | 2000 ppm (g) | |
|---|---|---|---|
|
| |||
| Pre-exposure (Day 1) | 284.0 ± 9.96 | 283.3 ± 7.63 | 283.5 ± 7.59 |
| Day 2 | 279.7 ± 14.11 | 281.1 ± 7.42 | 279.9 ± 8.50 |
| Day 7 | 318.4 ± 19.96 | 320.1 ± 18.66 | 320.1 ± 17.56 |
| Day 15 | 366.1 ± 14.35 | 371.7 ± 17.93 | 373.1 ± 19.68 |
Values are presented as mean ± SD.
Biochemical blood analysis of rats exposed to TBAc vapor by inhalation
| Day 2 | Day 7 | Day 15 | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Control | 500 ppm | 2000 ppm | Control | 500 ppm | 2000 ppm | Control | 500 ppm | 2000 ppm | |
|
| |||||||||
| n | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| AST | 73 ± 11.8. | 87 ± 26.0. | 109 ± 23.6* | 68 ± 14.5 | 75 ± 10.0 | 62 ± 8.0 | 060 ± 10.1 | 67 ± 7.9 | 66 ± 12.9 |
| ALT | 30 ± 1.4 | 27 ± 3.1 | 34 ± 5.2 | 34 ± 7.5 | 30 ± 5.8 | 29 ± 2.8 | 28 ± 3.7 | 32 ± 4.0 | 32 ± 2.6 |
| TBIL | 0.43 ± 0.052 | 0.47 ± 0.052 | 0.40 ± 0.000 | 0.47 ± 0.082 | 0.45 ± 0.055 | 0.48 ± 0.041 | 0.45 ± 0.055 | 0.37 ± 0.058 | 0.47 ± 0.103 |
| ALP | 1572 ± 188 | 1532 ± 226 | 1350 ± 265 | 1474 ± 394 | 1599 ± 306 | 1481 ± 292 | 1362 ± 226 | 1223 ± 245 | 1429 ± 449 |
Values are presented as mean ± SD.
n, number of animals.
*P < 0.05, significant difference as compared with the control.
AST, aspartate aminotransferase; ALT, alanine aminotransferase; TBIL, total bilirubin; ALP, alkaline phosphatase.
BALF analysis of rats exposed to TBAc vapor by inhalation
| Total number of cells in BALF | Percentage of cells in BALF (%) | |||
|---|---|---|---|---|
|
| ||||
| (Total number of cells/ml) × 105 | Macrophages | Neutrophils | Lymphocytes | |
|
| ||||
| Control | ||||
| Day 2 | 5.5 ± 1.4a | 99.22 | 0.33 | 0.44 |
| Day 7 | 4.6 ± 1.6 | 99.50 | 0.25 | 0.25 |
| Day 15 | 4.7 ± 1.3 | 99.22 | 0.39 | 0.39 |
| 500 ppm | ||||
| Day 2 | 3.8 ± 1.0 | 97.87 | 0.93 | 1.20 |
| Day 7 | 4.8 ± 2.5 | 98.00 | 1.13 | 0.87 |
| Day 15 | 3.1 ± 0.9 | 99.20 | 0.13 | 0.67 |
| 2000 ppm | ||||
| Day 2 | 3.8 ± 1.4 | 98.17 | 1.11 | 0.72 |
| Day 7 | 5.2 ± 3.4 | 99.47 | 0.00 | 0.53 |
| Day 15 | 4.4 ± 1.4 | 99.67 | 0.17 | 0.17 |
aValues are presented as mean ± SD.
BALF, bronchoalveolar lavage fluid.
Fig. 2.Cytospin images of alveolar cells in the bronchoalveolar lavage fluid (BALF) of rats exposed to TBAc vapor by inhalation. (A) Control - Day 2 (B) 500 ppm - Day 2 (C) 2000 ppm - Day 2 (D) Control - Day 7 (E) 500 ppm - Day 7 (F) 2000 ppm - Day 7 (G) Control- Day 15 (H) 500 ppm - Day 15 (I) 2000 ppm - Day 15.
Fig. 3.Histopathologic response in the lungs of rats exposed to TBAc vapor by inhalation (hematoxylin and eosin stain) . (A) Control -Day 2 (B) 500 ppm - Day 2 (C) 2000 ppm - Day 2 (D) Control - Day 7 (E) 500 ppm - Day 7 (F) 2000 ppm - Day 7 (G) Control - Day 15 (H) 500 ppm - Day 15 (I) 2000 ppm - Day 15.
Fig. 4.Histopathologic response in the liver of rats exposed to TBAc vapor by inhalation (hematoxylin and eosin stain) . (A) Control -Day 2 (B) 500 ppm - Day 2 (C) 2000 ppm - Day 2 (D) Control - Day 7 (E) 500 ppm - Day 7 (F) 2000 ppm - Day 7 (G) Control - Day 15 (H) 500 ppm - Day 15 (I) 2000 ppm - Day 15.
Fig. 5.Histopathologic response in the nasal cavity of rats exposed to TBAc vapor by inhalation (hematoxylin and eosin stain) . (A) Control - Day 2 (B) 500 ppm - Day 2 (C) 2000 ppm - Day 2 (D) Control - Day 7 (E) 500ppm - Day 7 (F) 2000 ppm - Day 7 (G) Control -Day 15 (H) 500 ppm - Day 15 (I) 2000 ppm - Day 15.
Histopathological changes in rats exposed to TBAc vapor by inhalation
| Day 2 | Day 7 | Day 15 | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Con | T1 | T2 | Con | T1 | T2 | Con | T1 | T2 | |
|
| |||||||||
| Nasal cavity | |||||||||
| flammatory cell foci | − | − | − | − | + (1) | − | − | − | − |
| Lung | |||||||||
| Inflammatory cell foci | − | + (1) | − | − | − | − | − | − | − |
| Foamy macrophages | + (1) | − | − | − | + (1) | + (1) | − | − | + (1) |
| Liver | |||||||||
| Hemopoiesis | + (3) | + (3) | + (4) | + (4) | + (4) | + (3) | + (1) | + (3) | + (4) |
| Inflammatory cell foci | + (5) | + (6) | + (2) | + (3) | + (2) | + (3) | + (4) | + (2) | + (3) |
| ++ (1) | ++ (1) | ||||||||
| Focal necrosis | − | − | + (1) | + (1) | − | − | − | ||
Histopathological changes were scored on the basis of the degree of abnormality in the tissues observed under a light microscope. The grading criteria used are as follows: −, no remarkable findings; +, minimal abnormality;++, slight abnormality;;+++, moderate abnormality;++++, marked abnormality;+++++, severe abnormality. Con, control (0 ppm) ; T1, 500 ppm; T2, 2000 ppm.